Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.
Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.
The Dow endured a turbulent week, marked by lingering trade tensions.
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want access to our free research report on AstraZeneca PLC (NYSE: ), all you need to do is sign up now by clicking the following link as the Company's...
AstraZeneca (AZN) and Merck's (MRK) Lynparza significantly delays disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.
--AstraZeneca and Merck's LYNPARZA is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance setting
Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.
Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.
Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.
AstraZeneca (NYSE: AZN) presented key data on the use of FARXIGA(R) (dapagliflozin) in diverse patient populations with type 2 and type 1 diabetes (T2D, T1D) at the American Diabetes Association...
Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.
Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
Stock Research Monitor: ABBV, AZN, and LLY
Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.